1. Wakabayashi, S, Mochizuki, J, Tomiyama, A, Shibata, S. Evaluation of cardiovascular effects and antiarrhythmic activity of KT-362 (5-[3-([2-(3,4-dimethoxyphenyl).-3thyl] amino)-1-oxopopyl]-2,3,4,5-tetrahydro-1,5-benzothiazepine fumarate, KT), a new intracellular Ca2+ inhibitor. Fed Proc 1986;45:803.
2. Farber, NE, Gross, GJ. Cardioprotective effects of a new vascular intracellular calcium antagonist, KT-362, in the stunned myocardium. J Pharmacol Exp Ther 1989;248:39?43.
3. Hester, R, Shibata, S. KT-362 related effects on intracellular calcium release and associated clinical potential, arrhythmias, myocardial ischemia and hypertension. Cardiovasc Drugs Ther 1990;4:1345?1354.
4. Sakata, K, Karaki, H. Effects of a novel smooth muscle relaxant, KT-362, on contraction and cytosolic Ca2+ level in the rat aorta. Br J Pharmacol 1991;102:174?178.
5. Shibata, S, Wakabayashi, S, Satake, N, Hester, RK, Ueda, S, Tomiyana, A. Mode of vasorelaxing action of 5 5-[3-([2-(3,4-dimethoxyphenyl)-ethyl]amino)-1-oxopropyl]-2,3,4,5-tetrahydro-1,5-benzothiazepine fumarate (KT-362), a new intracellular calcium antagonist. J Pharmacol Exp Ther 1987; 240:16?22.